19-221 - Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Status: open

S1800A, A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

Treatment for Lung Cancer

Contact Us Or call (251) 445-9834

Description

S1800A LUNGMAP sub-protocol trial has several investigational treatments that are being tested. The trial prescreening consists of a biomarker test which requires a patient’s tumor sample to be tested for specific genes and proteins. After the biomarker testing result come back the patient will then be assigned to a protocol according to the biomarker testing results. For this sub-study, the patient will be assigned to specific treatment with either the current standard of care treatment or the investigational therapy listed in the sub protocol.

Sponsors

This trial is sponsored by SWOG.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.